NCT05714371

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 618 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This was a retrospective cohort study using the PharMetrics database. The analysis was conducted using the most recent 5 years of data from the database, January 1, 2015, to October 30, 2020. Included patients were followed for outcome evaluation from the index date (first prescription of treatment, immunotherapy \[IO\], or targeted therapy \[TT\] following diagnosis of non-metastatic malignant melanoma and evidence of first lymph node resection), until the first occurrence or end of continuous eligibility or end of the study period.

Conditions

• Melanoma

Interventions

Type	Name	Description
DRUG	Nivolumab	Patients receiving nivolumab
DRUG	Ipilimumab + nivolumab	Patients receiving ipilimumab + nivolumab
DRUG	Pembrolizumab	Patients receiving pembrolizumab
DRUG	Dabrafenib + trametinib	Dabrafenib + trametinib

Timeline

• Start date: 2021-10-02
• Primary completion: 2022-01-27
• Completion: 2022-01-27
• First posted: 2023-02-06
• Last updated: 2023-02-06

Locations

1 site across 1 country: United States